ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV

We investigated whether apolipoprotein A-I (apoA-I) mimetic peptides 4F and 6F can be a novel therapeutic strategy to reduce blood and gut bioactive lipids, proinflammatory effects of endotoxin (LPS) and aberrant activation of cyclooxygenase 2 (COX-2) as instigators of increased risk for cardiometabolic disease in chronic treated HIV.

Source: Metabolism - Clinical and Experimental - September 9, 2021 Category: Biomedical Science Authors: M. Daskou, M. Sharma, W. Mu, R. Heymans, E. Ritou, V. Rezek, P. Hamid, A. Kossyvakis, S. Sen Roy, V. Grijalva, A. Chattopadhyay, J. Papesh, D. Meriwether, S.G. Kitchen, A.M. Fogelman, S.T. Reddy, T. Kelesidis Source Type: research